# Sean M Hays

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 63 papers | 2,505 citations | 159585 30 h-index | 197818 49 g-index |
| 63 all docs | 63 docs citations | 63 times ranked | 2348 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Derivation of Biomonitoring Equivalents for aluminium for the interpretation of population-level biomonitoring data. Regulatory Toxicology and Pharmacology, 2021, 122, 104913. | 2.7 | 3 |
| 2 | Derivation of biomonitoring equivalents (BE values) for bismuth. Regulatory Toxicology and Pharmacology, 2020, 114, 104672. | 2.7 | 2 |
| 3 | Biomonitoring Equivalents (BEs) for tetrabromobisphenol A. Regulatory Toxicology and Pharmacology, 2019, 102, 108-114. | 2.7 | 10 |
| 4 | Biomonitoring Equivalents for interpretation of urinary iodine. Regulatory Toxicology and Pharmacology, 2018, 94, 40-46. | 2.7 | 12 |
| 5 | Extrapolation of plasma clearance to understand species differences in toxicokinetics of bisphenol A. Xenobiotica, 2018, 48, 891-897. | 1.1 | 5 |
| 6 | Integration of mechanistic and pharmacokinetic information to derive oral reference dose and marginâ€ofâ€exposure values for hexavalent chromium. Journal of Applied Toxicology, 2018, 38, 351-365. | 2.8 | 19 |
| 7 | Screening-level Biomonitoring Equivalents for tiered interpretation of urinary 3-phenoxybenzoic acid (3-PBA) in a risk assessment context. Regulatory Toxicology and Pharmacology, 2018, 92, 29-38. | 2.7 | 29 |
| 8 | Risk assessment and Biomonitoring Equivalent for 2-ethylhexyl-2,3,4,5 tetrabromobenzoate (TBB) and tetrabromobenzoic acid (TBBA). Regulatory Toxicology and Pharmacology, 2017, 89, 186-192. | 2.7 | 1 |
| 9 | The role of human biological monitoring in health risk assessment. International Journal of Risk Assessment and Management, 2017, 20, 136. | 0.1 | 20 |
| 10 | Biomonitoring Equivalents for molybdenum. Regulatory Toxicology and Pharmacology, 2016, 77, 223-229. | 2.7 | 40 |
| 11 | Reduction of hexavalent chromium by fasted and fed human gastric fluid. II. Ex vivo gastric reduction modeling. Toxicology and Applied Pharmacology, 2016, 306, 120-133. | 2.8 | 16 |
| 12 | Biomonitoring Equivalents for interpretation of silver biomonitoring data in a risk assessment context. International Journal of Hygiene and Environmental Health, 2016, 219, 521-526. | 4.3 | 5 |
| 13 | Implementing a framework for integrating toxicokinetics into human health risk assessment for agrochemicals. Regulatory Toxicology and Pharmacology, 2016, 75, 89-104. | 2.7 | 18 |
| 14 | Deriving Biomonitoring Equivalents for selected E- and P-series glycol ethers for public health risk assessment. International Journal of Hygiene and Environmental Health, 2016, 219, 88-100. | 4.3 | 2 |
| 15 | California biomonitoring data: Comparison to NHANES and interpretation in a risk assessment context. Regulatory Toxicology and Pharmacology, 2015, 73, 875-884. | 2.7 | 12 |
| 16 | Derivation of human Biomonitoring Guidance Values for chlorpyrifos using a physiologically based pharmacokinetic and pharmacodynamic model of cholinesterase inhibition. Regulatory Toxicology and Pharmacology, 2015, 71, 235-243. | 2.7 | 16 |
| 17 | Variation in Urinary Flow Rates According to Demographic Characteristics and Body Mass Index in NHANES: Potential Confounding of Associations between Health Outcomes and Urinary Biomarker Concentrations. Environmental Health Perspectives, 2015, 123, 293-300. | 6.0 | 89 |
| 18 | A chronic oral reference dose for hexavalent chromiumâ€induced intestinal cancer. Journal of Applied Toxicology, 2014, 34, 525-536. | 2.8 | 123 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Interpreting Estrogen Screening Assays in the Context of Potency and Human Exposure Relative to Natural Exposures to Phytoestrogens. Birth Defects Research Part B: Developmental and Reproductive Toxicology, 2014, 101, 114-124. | 1.4 | 6 |
| 20 | Screening of population level biomonitoring data from the Canadian Health Measures Survey in a risk-based context. Toxicology Letters, 2014, 231, 126-134. | 0.8 | 43 |
| 21 | Sources of Variability in Biomarker Concentrations. Journal of Toxicology and Environmental Health - Part B: Critical Reviews, 2014, 17, 45-61. | 6.5 | 133 |
| 22 | Biomonitoring Equivalents for selenium. Regulatory Toxicology and Pharmacology, 2014, 70, 333-339. | 2.7 | 65 |
| 23 | Evaluation of urinary speciated arsenic in NHANES: Issues in interpretation in the context of potential inorganic arsenic exposure. Regulatory Toxicology and Pharmacology, 2014, 69, 49-54. | 2.7 | 47 |
| 24 | Evaluation of Biomonitoring Data from the CDC National Exposure Report in a Risk Assessment Context: Perspectives across Chemicals. Environmental Health Perspectives, 2013, 121, 287-294. | 6.0 | 126 |
| 25 | Evaluation of NHANES biomonitoring data for volatile organic chemicals in blood: Application of chemical-specific screening criteria. Journal of Exposure Science and Environmental Epidemiology, 2012, 22, 24-34. | 3.9 | 19 |
| 26 | Interpreting variability in population biomonitoring data: Role of elimination kinetics. Journal of Exposure Science and Environmental Epidemiology, 2012, 22, 398-408. | 3.9 | 78 |
| 27 | 2,4-D Exposure and risk assessment: Comparison of external dose and biomonitoring based approaches. Regulatory Toxicology and Pharmacology, 2012, 64, 481-489. | 2.7 | 20 |
| 28 | Hexavalent chromium reduction kinetics in rodent stomach contents. Chemosphere, 2012, 89, 487-493. | 8.2 | 34 |
| 29 | Development of Screening Tools for the Interpretation of Chemical Biomonitoring Data. Journal of Toxicology, 2012, 2012, 1-10. | 3.0 | 11 |
| 30 | Application of human biomonitoring (HBM) of chemical exposure in the characterisation of health risks under REACH. International Journal of Hygiene and Environmental Health, 2012, 215, 238-241. | 4.3 | 9 |
| 31 | Interpreting human biomonitoring data in a public health risk context using Biomonitoring Equivalents. International Journal of Hygiene and Environmental Health, 2012, 215, 145-148. | 4.3 | 37 |
| 32 | Biomonitoring Equivalents for benzene. Regulatory Toxicology and Pharmacology, 2012, 62, 62-73. | 2.7 | 30 |
| 33 | Human biomonitoring as a pragmatic tool to support health risk management of chemicals â€“ Examples under the EU REACH programme. Regulatory Toxicology and Pharmacology, 2011, 59, 125-132. | 2.7 | 49 |
| 34 | Biomonitoring Equivalents for 2,2â€²,4,4â€²,5-pentabromodiphenylether (PBDE-99). Regulatory Toxicology and Pharmacology, 2011, 60, 165-171. | 2.7 | 20 |
| 35 | Biomonitoring Equivalents for DDT/DDE. Regulatory Toxicology and Pharmacology, 2011, 60, 172-180. | 2.7 | 47 |
| 36 | Biomonitoring Equivalents for di-isononyl phthalate (DINP). Regulatory Toxicology and Pharmacology, 2011, 60, 181-188. | 2.7 | 37 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Biomonitoring Equivalents for deltamethrin. Regulatory Toxicology and Pharmacology, 2011, 60, 189-199. | 2.7 | 35 |
| 38 | Assessment of margin of exposure based on biomarkers in blood: An exploratory analysis. Regulatory Toxicology and Pharmacology, 2011, 61, 44-52. | 2.7 | 9 |
| 39 | Biomonitoring-based risk assessment for hexabromocyclododecane (HBCD). International Journal of Hygiene and Environmental Health, 2011, 214, 179-187. | 4.3 | 30 |
| 40 | Human biomonitoring assessment values: Approaches and data requirements. International Journal of Hygiene and Environmental Health, 2011, 214, 348-360. | 4.3 | 156 |
| 41 | Consideration of dosimetry in evaluation of <scp>ToxCast</scp>â„¢ data. Journal of Applied Toxicology, 2011, 31, 741-751. | 2.8 | 19 |
| 42 | Chemical-specific screening criteria for interpretation of biomonitoring data for volatile organic compounds (VOCs) â€“ Application of steady-state PBPK model solutions. Regulatory Toxicology and Pharmacology, 2010, 58, 33-44. | 2.7 | 30 |
| 43 | Biomonitoring Equivalents for inorganic arsenic. Regulatory Toxicology and Pharmacology, 2010, 58, 1-9. | 2.7 | 71 |
| 44 | Biomonitoring equivalents for hexachlorobenzene. Regulatory Toxicology and Pharmacology, 2010, 58, 25-32. | 2.7 | 27 |
| 45 | Biomonitoring Equivalents for triclosan. Regulatory Toxicology and Pharmacology, 2010, 58, 10-17. | 2.7 | 35 |
| 46 | Biomonitoring Equivalents for bisphenol A (BPA). Regulatory Toxicology and Pharmacology, 2010, 58, 18-24. | 2.7 | 65 |
| 47 | Public health interpretation of trihalomethane blood levels in the United States: NHANES 1999â€“2004. Journal of Exposure Science and Environmental Epidemiology, 2010, 20, 255-262. | 3.9 | 34 |
| 48 | Biomonitoring Data for 2,4-Dichlorophenoxyacetic Acid in the United States and Canada: Interpretation in a Public Health Risk Assessment Context Using Biomonitoring Equivalents. Environmental Health Perspectives, 2010, 118, 177-181. | 6.0 | 36 |
| 49 | Derivation of Biomonitoring Equivalents for di(2-ethylhexyl)phthalate (CAS No. 117-81-7). Regulatory Toxicology and Pharmacology, 2009, 55, 249-258. | 2.7 | 38 |
| 50 | Derivation of Biomonitoring Equivalents for cyfluthrin. Regulatory Toxicology and Pharmacology, 2009, 55, 268-275. | 2.7 | 25 |
| 51 | Derivation of Biomonitoring Equivalents for di-n-butyl phthalate (DBP), benzylbutyl phthalate (BzBP), and diethyl phthalate (DEP). Regulatory Toxicology and Pharmacology, 2009, 55, 259-267. | 2.7 | 56 |
| 52 | Using Biomonitoring Equivalents to interpret human biomonitoring data in a public health risk context. Journal of Applied Toxicology, 2009, 29, 275-288. | 2.8 | 81 |
| 53 | Perspective on serum dioxin levels in the United States: an evaluation of the NHANES data. Journal of Exposure Science and Environmental Epidemiology, 2009, 19, 435-441. | 3.9 | 37 |
| 54 | Guidelines for the derivation of Biomonitoring Equivalents: Report from the Biomonitoring Equivalents Expert Workshop. Regulatory Toxicology and Pharmacology, 2008, 51, S4-S15. | 2.7 | 147 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Biomonitoring Equivalents (BE) dossier for trihalomethanes. Regulatory Toxicology and Pharmacology, 2008, 51, S68-S77. | 2.7 | 18 |
| 56 | Biomonitoring Equivalents (BE) dossier for 2,4-dichlorophenoxyacetic acid (2,4-D) (CAS No. 94-75-7). Regulatory Toxicology and Pharmacology, 2008, 51, S37-S48. | 2.7 | 51 |
| 57 | Guidelines for the communication of Biomonitoring Equivalents: Report from the Biomonitoring Equivalents Expert Workshop. Regulatory Toxicology and Pharmacology, 2008, 51, S16-S26. | 2.7 | 99 |
| 58 | Biomonitoring Equivalents (BE) dossier for cadmium (Cd) (CAS No. 7440-43-9). Regulatory Toxicology and Pharmacology, 2008, 51, S49-S56. | 2.7 | 82 |
| 59 | Biomonitoring Equivalents (BE) dossier for toluene (CAS No. 108-88-3). Regulatory Toxicology and Pharmacology, 2008, 51, S27-S36. | 2.7 | 26 |
| 60 | Biomonitoring Equivalents (BE) dossier for acrylamide (AA) (CAS No. 79-06-1). Regulatory Toxicology and Pharmacology, 2008, 51, S57-S67. | 2.7 | 36 |
| 61 | Derivation of Biomonitoring Equivalent (BE) Values for 2,3,7,8-Tetrachlorodibenzo-p-Dioxin (TCDD) and Related Compounds: A Screening Tool for Interpretation of Biomonitoring Data in a Risk Assessment Context. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2008, 71, 1499-1508. | 2.3 | 20 |
| 62 | Risk assessment for children exposed to decabromodiphenyl (oxide) ether (deca) in the United States. Integrated Environmental Assessment and Management, 2006, 2, 2-12. | 2.9 | 6 |
| 63 | Risk assessment for children exposed to decabromodiphenyl (oxide) ether (Deca) in the United States. Integrated Environmental Assessment and Management, 2006, 2, 2-12. | 2.9 | 3 |